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Abstract. Breast cancer risk drastically increases in indi-
viduals with a heterozygous germline BRCA1 or BRCA2 
mutation, while it is estimated to equal the population risk 
for relatives without the familial mutation (non-carriers). The 
aim of the present study was to use a G2 phase-specific micro-
nucleus assay to investigate whether lymphocytes of healthy 
BRCA2 mutation carriers are characterized by increased 
radiosensitivity compared to controls without a family history 
of breast/ovarian cancer and how this relates to healthy 
non-carrier relatives. BRCA2 is active in homologous recom-
bination, a DNA damage repair pathway, specifically active in 
the late S/G2 phase of the cell cycle. We found a significantly 
increased radiosensitivity in a cohort of healthy BRCA2 
mutation carriers compared to individuals without a familial 
history of breast cancer (P=0.046; Mann-Whitney U test). At 
the individual level, 50% of healthy BRCA2 mutation carriers 
showed a radiosensitive phenotype (radiosensitivity score of 
1 or 2), whereas 83% of the controls showed no radiosensi-
tivity (P=0.038; one-tailed Fisher's exact test). An odds ratio 
of 5 (95% CI, 1.07-23.47) indicated an association between 
the BRCA2 mutation and radiosensitivity in healthy mutation 
carriers. These results indicate the need for the gentle use of 
ionizing radiation for either diagnostic or therapeutic use in 
BRCA2 mutation carriers. We detected no increased radiosen-
sitivity in the non-carrier relatives.
Introduction
BRCA1 and BRCA2 heterozygous mutation carriers have 
a strongly increased risk to develop breast cancer (BC) and 
ovarian cancer (OC). The lifetime risk to develop BC is 70-80% 
for BRCA1 mutation carriers and 50-60% for BRCA2 muta-
tion carriers (1). For relatives who did not inherit the germline 
BRCA1/2 mutation segregating in the family (non-carrier rela-
tives), the risk of BC occurrence is generally estimated to be 
as low as the risk assessed in the general population. This may 
imply that intensified BC detection screening, using, amongst 
others, mammography screening and MRI, as applied in 
individuals at high-risk is unnecessary in non-carriers (2-7). 
However, one study reported a 2-5-fold increase in BC 
occurrence in non-carriers of families with either BRCA1 
or BRCA2 mutations (8). Another study reported a younger 
than expected age at diagnosis of BC for non-carriers, that 
was most evident in BRCA1 families (9). Moreover, one 
study by Evans et al detected a possible higher relative risk 
for BC in non-carrier relatives of BRCA2 families, compared 
to non-carriers in BRCA1 families (10). In summary, these 
studies suggest that DNA alterations (for example SNPs) in 
other genes may modify the relative risk for the development 
of BC in non-carriers, compared to the general population. 
Moreover, the authors of these studies recommend targeted 
BC detection screening using for example mammography in 
non-carriers at a frequency comparable to the intensive BC 
screening performed in individuals at high-risk.
Both BRCA1 and BRCA2 are caretaker genes playing 
different roles in the repair of DNA double-strand breaks 
(DSB), induced by exposure to genotoxic agents such as 
ionizing radiation (IR). While BRCA1 has a more general 
function in the detection and signaling of a DSB and in the 
activation of the G2/M cell cycle checkpoint, BRCA2 exerts 
a specific function in the recruitment of RAD51 recombinase 
to the DSB site. This latter event is essential for the activation 
of the homologous recombination (HR) pathway, that relies on 
the undamaged sister chromatid as a template for resynthesis 
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of the damaged strand. This occurs in the late S and G2 phase 
of the cell cycle and leads to error-free repair of DSB (1).
Knowing that both BRCA1 and BRCA2 are important in 
the repair of DSB, exposure of mutation carriers to IR, a potent 
inducer of DSB, for either diagnostic or therapeutic purposes 
appears to be counterintuitive, as mutation carriers may be 
more prone to develop radiation-induced BC (11).
Radiosensitivity of BRCA1 mutation carriers has previ-
ously been reported in the literature and was investigated and 
confirmed by our research group by means of the G2 micro-
nucleus (MN) assay in combination with an evaluation of the 
G2/M checkpoint efficiency in peripheral blood lymphocytes of 
healthy BRCA1 mutation carriers compared to healthy volun-
teers (12). However, the impact of IR on heterozygous cells of 
healthy BRCA2 mutation carriers remains to be elucidated.
To date, several cohort studies were able to prove a posi-
tive correlation between exposure to diagnostic X-rays and BC 
risk in BRCA2 mutation carriers (11,13,14). Others however, 
could not detect a similar correlation (15-18). Furthermore, 
Bernstein et al detected no increased induction of contralat-
eral BC upon exposure to radiotherapy in BRCA2 mutation 
carriers (19). Such discrepancies are likely due to differences 
in inclusion criteria, data acquisition and other issues of the 
studies. It is however difficult and unethical to design long-term 
unbiased studies to evaluate the relationship between BRCA2 
mutations, the exposure to diagnostic or therapeutic radiation 
and BC risk. In vitro chromosomal assays are effective tools 
to investigate radiosensitivity. Chromosomal radiosensitivity 
testing on lymphocytes from BRCA2 mutation carriers has 
been performed with techniques such as the G0 MN and the 
G2 assays for chromatid breaks, occasionally enhanced with 
a whole-chromosome painting FISH (20-25). However, for 
several of these studies, it was unclear whether the BRCA2 
heterozygotes were healthy individuals or BC patients, which 
was previously broached by Baeyens et al (20). Furthermore, 
differences in the experimental setup make comparisons 
between studies difficult (26). Despite these differences, all 
but one study was able to detect an elevated chromosomal 
radiosensitivity in BC patients with a BRCA2 mutation. 
However, no comparison was made with sporadic BC patients. 
The study of Baeyens et al previously demonstrated enhanced 
radiosensitivity in both BC patients with a BRCA1/2 mutation 
and sporadic BC patients, suggesting that the enhanced sensi-
tivity may not be the result of the mutation (20). No univocal 
results were achieved for healthy BRCA2 mutation carriers. 
Radiosensitivity in non-carrier relatives has not been studied 
extensively, only one study reported no increased radiosen-
sitivity measured with the G0 MN and G2 chromatid break 
assay in a small cohort (n=10) of relatives of both BRCA1 and 
BRCA2 families without the familial mutation when compared 
to a population cohort (20).
In the present study, we aimed to investigate chromosomal 
radiosensitivity in healthy BRCA2 mutation carriers by means 
of the G2 MN assay. We previously used this assay and 
confirmed radiosensitivity in healthy BRCA1 mutation carriers 
(n=18) compared to healthy controls without a family history 
of BC or OC (n=20) (12), and in an ataxia-telangiectasia patient 
and family members (27). In addition, we also included healthy 
relatives not carrying the familial germline BRCA1 or BRCA2 
mutation in the present study. This cohort of non-carriers 
was included to evaluate radiosensitivity in individuals with 
a comparable genetic background, but without the familial 
BRCA1 or BRCA2 mutation.
Materials and methods
Sample collection. Blood samples were collected from 
individuals consulting the Centre for Medical Genetics of 
the Ghent University Hospital (CMG; Ghent, Belgium), in 
the context of predictive testing for hereditary BC. Heparin 
blood samples were collected for the G2 MN assay. In addi-
tion, EDTA samples were collected for mutation analysis. We 
collected blood samples from 18 BRCA2 mutation carriers and 
17 subjects from both BRCA1 (n=9) and BRCA2 (n=8) fami-
lies not showing the familial mutation (non-carriers). None of 
the individuals selected for the present study had developed 
cancer at the time of the blood sample collection. We also 
selected 18 blood samples from a historical cohort of healthy 
volunteers without a personal or familial history of BC or OC 
for optimal age and gender match, to determine the normal 
distribution of MN yields in unaffected individuals from the 
general population (12).
The present study was approved by the Ethics Committee 
of Ghent University Hospital (B67020111641 d.d. 20/09/2011) 
and all participants signed an informed consent.
Molecular analysis. All healthy individuals selected for the 
present study had a family history of BC or OC and a mutation 
in either BRCA1 or BRCA2 was identified in each proband. All 
BRCA2 mutation carriers are heterozygous for an unequivocal 
deleterious mutation. This was confirmed by Sanger sequencing 
of the relevant amplicon. Sanger sequencing was performed 
on the ABI3730XL instrument using the BigDye® Terminator 
Cycle Sequencing kit (Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer's instructions; sequences were 
analyzed using the SeqPilot software (JSI Medical Systems 
GmbH, Ettenheim, Germany).
Molecular analyses were not performed in healthy volun-
teers due to the absence of a personal or familial anamnesis 
for BC or OC.
The G2 MN assay. The G2 MN assay was performed as previ-
ously described (12). In brief, heparinized blood was cultured 
in the presence of phytohaemagglutinin (PHA; 2% v/v; 
Gibco, Grand Island, NY, USA) to stimulate T-lymphocyte 
division. After 3 days, a population of cycling lymphocytes 
was obtained and the culture was irradiated with a 2 Gy dose 
of 60Co γ-rays. We opted to use a dose of 2 Gy as this is a 
well-accepted dose for chromosomal radiosensitivity testing in 
lymphocytes (20-22,24). Immediately after irradiation, cyto-
chalasin B (cyto B; 6 µg/ml; Sigma-Aldrich, St. Louis, MO, 
USA) was added to all cultures, including a non-irradiated 
culture. Cyto B blocks the cytokinesis and allows the iden-
tification of first-division cells as a binucleated (BN) cell. 
After an incubation period of 8 h, all cultures were fixed 
with the sequential addition of KCl (75 mM), a solution of 
methanol, acetic acid and Ringer (4:1:5), and a combination 
of methanol and acetic acid (4:1) to pelleted cells. Finally, the 
cell suspension was concentrated and spread on slides. Slides 
were stained with 4',6-diamidino-2-phenlylindole (DAPI) and 
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scanned with a Metafer 4 platform and MN search software 
(MetaSystems GmbH, Altlussheim, Germany). The automated 
image analysis system selects BN cells and determines the 
number of MN/BN cells. BN cells and MN selection are manu-
ally checked for false positives or false negatives. For each 
condition, 2 cultures were prepared and 2 slides/culture were 
analyzed. A minimum of 600 BN cells were scored/coded 
slide. To assess individual radiosensitivity, a radiosensitivity 
score (RS score) was determined. The mean and SD of the 
MN yield of the group of healthy volunteers (HV) was set as 
the cut-off value to determine the RS score of HV, BRCA2 
mutation carriers and non-carrier relatives. An MN yield 
higher than the meanHV + 1SDHV was scored as 1, indicating 
a milder radiosensitive phenotype, whereas a result higher 
than the meanHV + 2SDHV was scored as 2, and indicated a 
more severe radiosensitive phenotype. When the individual 
value was lower than the meanHV + 1SDHV, a score of 0 was 
attributed to the tested subject.
Statistical analysis. Age and gender differences among the 
3 groups were judged by means of a one-way ANOVA and 
Chi-square test, respectively. The median, interquartile 
range, average and standard deviation of micronuclei yields 
(number of MN/1,000 BN cells) were assessed in each group 
of subjects. Intergroup differences of MN yields between HV, 
BRCA2 mutation carriers and non-carrier relatives of BRCA1 
and BRCA2 pedigrees were analyzed by the Mann-Whitney-
Wilcoxon test. A one-tailed Fisher's exact test was performed 
to compare the unpaired and independent proportion of 
patients showing a radiosensitive phenotype, evaluated by RS 
scoring. For both assays a 5% α error was set as the limit for 
statistical significance. The odds ratio (OR) was calculated, 
based on the RS scores in healthy individuals and BRCA2 
mutation carriers, to assess the association between the pres-
ence of a BRCA2 mutation and radiosensitivity according to 
the following formula:
The 95% confidence interval (CI) was used as a proxy for 
significance. The VassarStats platform and the SPSS software 
(IBM, version 23) were used to perform statistical analysis.
Results
The mean age did not significantly differ for the HV 
(35.3 years), the BRCA2 mutation carriers (40.9 years) and 
the non-carrier relatives (40.0 years) (P=0.56; one-way 
ANOVA). In addition, no significant difference in gender 
distribution was observed for these 3 groups (68, 61 and 
71% of the individuals were female, respectively) (P=0.84; 
Chi-square test). The number of spontaneously occurring 
micronuclei (MN yields in non-irradiated samples) was 
not significantly different among the 3 groups of enrolled 
subjects (Table I and Fig. 1).
Compared to HV without a family history of BC/OC, BRCA2 
mutation carriers showed a significant increase in mean MN 
yields after exposure to 2 Gy IR (P=0.046; Mann-Whitney). 
Conversely, the radiation-induced MN yields were similar in 
relatives who did not inherit the familial BRCA1/2 mutation 
and HV without a family history of BC/OC. The mean MN 
yield in BRCA2 mutation carriers was higher compared to the 
mean yield in non-carriers (86.11 vs. 68.11 MN/1,000 BN cells, 
respectively). This difference, however, was not significant 
(P=0.298; Mann-Whitney), probably due to the small cohort 
and the high SD (Table I and Fig. 1). Furthermore, MN yields 
did not differ between non-carrier relatives from BRCA1 or 
BRCA2 pedigrees (Table II).
Figure 1. Mean G2 micronucleus (MN) yield. Mean MN yield for healthy 
volunteers, healthy relatives who did not inherit the familial BRCA1/2 muta-
tion and healthy BRCA2 mutation carriers; *P<0.05 indicates a significant 
difference determined by Mann-Whitney U test. Error bars represent the 
standard error of the mean. BN, binucleated; MC, mutation carriers.
Table I. Overview of the median, interquartile range, mean and 
SD of the micronucleus yield (#MN/1,000 BN).
Group data 0 Gy 2 Gy
Healthy volunteers (HV)
  Median 12 56
  Interquartile range 9.75 27.5
  Mean 14.33 61.22
  SD 8.85 21.73
BRCA2 mutation carriers (MC)
  Median 14 74
  Interquartile range 7.75 54.75
  Mean 16.11 86.11
  SD 6.91 41.87
P-value vs. healthy volunteers 0.177 0.046
(Mann-Whitney)
Relatives who did not inherit
the familial BRCA1/2 mutation
  Median 16 69
  Interquartile range 8 26
  Mean 17.23 68.11
  SD 7.74 22.30
  P-value vs. healthy volunteers 0.116 0.400
  (Mann-Whitney)
SD standard deviation, MN micronucleus, BN binucleated cells.
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The individual MN yields after exposure to 2 Gy and 
the RS score for each BRCA2 mutation carrier, non-carrier 
relative and healthy volunteer group are listed in Table III. 
Furthermore, Table III shows mutational data (both nucleo-
tide and protein nomenclature) and individuals with the same 
family ID are related. Fig. 2 shows the distribution of the 
3 groups for the different RS scores. A significantly higher 
number of BRCA2 mutation carriers (n=9/18; 50%) showed 
increased RS scores (score 1 or 2) compared to HV (n=3/18; 
17%) (P=0.038; one-tailed Fisher's exact test). For the relatives 
who did not inherit the familial germline mutation only 24% 
(n=4/17) showed an elevated radiosensitivity at the individual 
level. RS scoring in related individuals (see family ID in 
Table III) however shows some variation. An OR of 5 (95% CI, 
1.07-23.46) for BRCA2 mutation carriers vs. HV, indicates a 
significant association between the presence of a BRCA2 
mutation and radiosensitivity according to our criteria.
All but one of the 18 mutation carriers enrolled in the 
present study were heterozygous for a mutation predicted to 
result in a premature termination codon (PTC). The patient 
with the deleterious missense mutation [BRCA2 c.8167G>C; 
p.(Asp2723His)] obtained an RS score of 2.
Discussion
Results of the G2 micronucleus (MN) assay performed after 
exposure to 2 Gy γ-rays showed a significantly increased 
radiosensitivity in healthy BRCA2 mutation carriers compared 
to healthy controls. Previous studies with a large number of 
different techniques were able to demonstrate enhanced radio-
sensitivity in BC patients with a BRCA2 mutation, however, 
no univocal results were achieved for healthy BRCA2 muta-
tion carriers (20-25). Non-carrier relatives of either BRCA1 
or BRCA2 families did not show an increased radiosensitive 
phenotype compared to the cohort of healthy volunteers, which 
is in agreement with the study of Baeyens et al (20). We previ-
ously performed the G2 MN assay in a group of 18 healthy 
BRCA1 mutation carriers, and found a significantly increased 
MN yield after exposure to 2 Gy γ-rays (12). These findings 
are analogous to the results of the present study, performed 
in healthy carriers of pathogenic BRCA2 mutations. Fig. 3 
shows the integration of the data from healthy BRCA1 muta-
tion carriers in the present study. The detection of an increased 
mean MN yield in both BRCA1 and BRCA2 mutation carriers 
after exposure to ionizing radiation can be explained by their 
mutual role in DNA double-strand break repair reviewed by 
Roy et al (1).
In our previous study we also analyzed the G2/M check-
point activity by the addition of caffeine, an agent abrogating the 
G2/M checkpoint, to the irradiated cultures and demonstrated a 
significantly impaired checkpoint activation in BRCA1 mutation 
carriers compared to healthy volunteers (12). Analysis of the 
G2/M checkpoint activation in the current BRCA2 cohort did 
not reveal a significant difference (data not shown). This result 
is in agreement with the fact that BRCA2 is not activated in 
this particular checkpoint pathway as reviewed by Roy et al (1), 
but does not support the data obtained by Menzel et al (28), 
suggesting a role for BRCA2 as a regulator of G2 checkpoint 
maintenance following DNA damage introduced in a human 
osteosarcoma cell line (U2OS) expressing dominant-negative 
p53 by a high-dose of ionizing radiation (6 Gy).
The role of BRCA2 in the HR pathway, a DNA repair 
pathway active in the S and G2 phase of the cell cycle, is exten-
sively reported in literature (1). The present study, focusing on 
radiosensitivity testing of lymphocytes in these phases of the 
cell cycle, showed an OR of 5 (95% CI, 1.07-23.47) for healthy 
individuals with a heterozygous BRCA2 mutation compared to 
healthy controls. This indicates a positive association between 
the presence of a BRCA2 mutation and radiosensitivity that 
could be attributed to deficient HR capacity in heterozygous 
cells.
Two independent research groups have reported a 
decreased DSB repair capacity in BRCA2 heterozygous cells. 
Table II. Overview of median, interquartile range, mean and 
SD of the micronucleus yield (#MN/1,000 BN) for healthy 
relatives who did not inherit the familial germline BRCA1/2 
mutation.
Goup data 0 Gy 2 Gy
Relatives who did not inherit
the familial BRCA1 mutation
(n=9)
  Median 14 66
  Interquartile range 12 57
  Mean 16.44 69.04
  SD 6.88 27.45
Relatives who did not inherit
the familial BRCA2 mutation
(n=8)
  Median 16 70
  Interquartile range 12.75 51.71
  Mean 18.11 66.98
  SD 9.18 16.59
  P-value vs. BRCA1 non-carriers 0.7339 0.9601
  (Mann-Whitney)
SD standard deviation, MN micronucleus, BN binucleated cells.
Figure 2. Radiosensitivity scoring. Distribution (%) of healthy volunteers, 
healthy relatives who did not inherit the familial BRCA1/2 mutation and 
healthy BRCA2 mutation carriers with different RS scores. RS score 0 
indicates no increased radiosensitivity, RS score 1 indicates a milder radio-
sensitive phenotype and RS score 2 reflects a more severe radiosensitive 
phenotype. RS, radiosensitivity.
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Keimling et al used an enhanced green fluorescent protein 
(EGFP)-based assay to report impaired HR capacity in 
lymphoblastoid cells with a BRCA2 monoallelic truncating 
frameshift mutation. They confirmed this decrease in HR 
capacity in a BRCA2-knockdown HeLa cell line (29). 
Arnold et al demonstrated distinct defects in DNA DSB 
repair in lymphoblastoid cell lines (LCLs) from heterozygous 
BRCA2 mutation carriers through analysis of γ-H2AX repair 
kinetics (30). Although, the latter study did not focus on DNA 
repair by HR, it indicates a malfunction of DSB repair in 
LCLs from BRCA2 mutation carriers that could be attributed 
to diminished HR activity.
Most mutation carriers enrolled in the present study 
(n=17/18, 94%) had a mutation resulting in a premature 
termination codon (PTC). The presence of a PTC mutation is 
expected to activate nonsense-mediated decay of the gene tran-
script. Previous research from various groups including ours, 
demonstrated a reduction in mutant mRNA to approximately 
half of the WT mRNA levels in lymphocytes of individuals 
with a PTC mutation in BRCA1 (12,31,32). Arnold et al (30) 
detected a similar mutant mRNA reduction for BRCA2 muta-
tions leading to a PTC. Furthermore, Arnold et al (30) and 
Keimling et al (29) report distinct reduced protein levels in 
LCLs from heterozygous BRCA2 mutation carriers, although 
quantitative analysis of this variation was not performed. 
Previously, haploinsufficiency has been suggested as the 
mechanism for hereditary BC development in BRCA1 and 
BRCA2 mutation carriers (33). In the present study, a higher 
than expected number of radiosensitive individuals in the 
BRCA2 mutation carriers indicates that haploinsufficiency 
may also be responsible for the radiosensitive phenotype in 
carriers of a mutation generating a PTC. In the present study, 
only one individual with a deleterious missense mutation was 
included. This substitution results in an amino acid change at 
position p.2723 and impairs protein functionality as shown by 
a homology-directed DNA break-repair functional assay (34). 
For this individual we obtained a high RS score of 2. Further 
research in larger patient cohorts with different types of 
mutations is needed to evaluate whether the type of mutation 
influences the radiosensitive phenotype or whether there are 
additional parameters determining this phenotype.
Results of the G2 MN assay showed no increased radiosen-
sitivity in the group of non-carrier relatives of both BRCA1 and 
BRCA2 families compared to a group of healthy volunteers. 
Furthermore, only 24% of non-carriers showed an elevated 
radiosensitivity at the individual level (RS score 1 or 2). This 
was not significantly different from the fraction of healthy 
volunteers (17%) that was found to have an increased RS 
score. In addition, no difference was observed between 
non-carriers from BRCA1 (RS score, 0 in 7/9 investigated 
relatives) or BRCA2 families (RS score, 0 in 6/8 investigated 
relatives). However, we observed some variation within the 
different groups. We hypothesize that modifiers may play a 
role: indeed, selected SNPs in DNA-damage repair genes and 
other common variants have been associated with increased 
radiosensitivity (35-37) and increased BC risk (35,38). Further 
and larger studies are needed to evaluate the subtle influence 
of possible modifying factors on BC risk and radiosensitivity.
In conclusion, the present study demonstrated higher 
radiosensitivity in healthy BRCA2 mutation carriers compared 
to healthy volunteers by means of the G2 MN assay after expo-
sure of peripheral blood lymphocytes to a dose of 2 Gγ-rays. 
No increased radiosensitivity was observed in non-carrier 
relatives of BRCA1 and BRCA2 families. When evaluating 
radiosensitivity at the individual level, a significantly higher 
proportion of BRCA2 mutation carriers (50%) showed a mild 
or more severe radiosensitivity compared to healthy volunteers 
(17%) and non-carriers (24%). Furthermore, an OR of 5 indi-
cated a positive association between the BRCA2 mutation and 
an increased radiosensitivity in healthy mutation carriers. 
These results indicate that care should be taken when applying 
ionizing radiation for either diagnostic or therapeutic purposes 
in BRCA2 mutation carriers. However, a study including 
a larger population of subjects carrying different types of 
BRCA2 mutations and non-carriers, must be performed to 
further elucidate the effect of each single mutation on the 
radiosensitive phenotype and the influence of possible under-
lying factors.
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